WHY ATTEND
With many biologic patents set to lose exclusivity in 2023 a patent cliff is on the way. Generic, biosimilar and innovator biopharma companies are in different positions and will need to react differently to these changing market circumstances. Additionally, the face of biologics is changing with and increasing number of gene therapy and antibody-drug conjugate options adding to and sometimes taking the place of “naked antibodies”. The Global Biologics, Cell and Gene Summit is perfect place to address these changes with leading industry experts from across the IP, Regulatory and Commercial fields.
Highlights include:
- Understanding how the UPC will shape the future patent landscape for biologic products
- Discover the latest global perspective on the situation for biologics/biosimilars in Europe, US, and Asia.
- Understand the latest regulatory framework for biologic products.
- Learn the latest trends within the biologics marketplace with the commercial, regulatory and IP updates on Cell and Gene products.
HOW TO GET INVOLVED
ATTEND AS A DELEGATE
Join us to network with colleagues and gain insights from industry experts on how you can create new innovative commercial and legal strategies, overcome market barriers, and take advantage of the growing opportunities in the biologic marketspace.
PARTNER WITH US
Based on your objectives we can create bespoke packages especially for you.
From presenting your experience on stage to hosting networking drinks. You can partner with us to showcase your brand and make valuable new connections. Opportunities predominently lie in 3 main categories: Thought Leadership, Branding, and Networking.
Discuss your objectives with Duncan Henderson, Senior Commercial Partnerships Manager; [email protected] or register your your interest in sponsorship here:
FIND OUT MORE ABOUT THIS YEARS SUMMIT
We're excited to be returning to Brussels this year to uncover the latest global standings in the European, US, and Asian for biologics/biosimilars marketplaces. We've compiled an agenda of some top in-house and private practice legal representatives with sessions exploring:
- The latest legal regulatory framework
- The biologics patent landscape
- The effective commercialisation of biologic products
Fill out this quick form to access the full agenda
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick the "YES" box.
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
2023 Global Biologics, Cell and Gene Legal Summit
GLOBAL BIOLOGICS, CELL & GENE LEGAL SUMMIT 2023 COMMUNITY
From our advisory board and speakering faculty to our media and strategic partners, our series wouldn't be possible without the contributions of our esteemed community of in-house legal representatives, trademark/patent private practice lawyers and legal press
2023 Speakers
Alex Moulson
Christof Bull
Rob Aerts
Nicolas Pourbaix
Georgia Gavriilidou
Georgia is currently holding the position of the Associate General Counsel (Executive Director) at Amgen, coordinating the legal strategy at a European Level on legal regulatory topics (including medicinal devices, pharmacovigilance, combination products, etc), market access and litigation. In her former role at the EMA, she was the lead lawyer on the implementation of major pharmaceutical legislation including the advanced therapies legislation and pharmacovigilance legislation. She has also served as chief legal adviser on a wide array of pharmaceutical issues relating to fixed-dose combination medicinal products, orphan and pediatric medicinal products, parallel distribution, invented names and validation/pre-authorization issues. Her experience also covers counseling clients on life-cycle management of bio/pharma medicinal products, including the maximization of IP regulatory rights and representing clients on legal strategy before the National / EU Authorities, the UK and EU Courts (for EMA and clients).
Poopak Banky
Tamaris Bucher
Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.
She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.
Tamaris is both a registered European Patent Attorney and Swiss Patent Attorney. Additionally, she has a background in Australian patent law, having completed a Master of Industrial Property at the University of Technology, Sydney.
Katherine Helm
Kaushal Joshi
Michael Swifta
Eva Temkin
Kirsten Broeckers
Adrian Spillmann
Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.
His areas of expertise include protection of prophylactics, therapeutics, and diagnostics for infectious diseases, immunological disorders, cancerous diseases, neurodegenerative disorders and metabolic disorders, vaccine technologies, antibody technologies, production of biological and chemical compounds, new medical uses, and formulations of known compounds.
After earning his Ph.D. at the University of Zurich, Switzerland, Adrian was a Consultant at Deloitte, followed by a 7-year stay in various positions in the patent department at Novartis. Furthermore, Adrian was Senior Patent Attorney at Ablynx, an antibody company in Belgium, for three years.
Adrian is a European and Swiss-registered patent attorney and received his LLM from the University of Law in London.
Sharada Devarasetty
Sharada has spent the last decade building global IP strategies to launch biosimilars. She started her career in the US with the patent litigation group at Proskauer Rose, participating in several ITC litigations in addition to her district court docket. In 2012, she moved to Boehringer Ingelheim to begin her career in the then-new and exciting biosimilars market. There she helped build strategies for most of the first wave biosimilar, in addition to advising her client how to prepare for global biosimilar litigation. More recently, she leads the biosimilar IP team at Sandoz, a global leader in biosimilars, for the next wave of launches.
Hilary Pioro
Chad Shear
Chad is a principal in the firm’s San Diego office and is the go-to patent litigator for numerous multinational life sciences companies — including Gilead, GSK, iCeutica, Iroko, Coherus Biosciences and Dainippon Sumitomo Pharma — whose marquee products deliver billions of dollars in annual revenues. He draws on his litigation experience, extensive network of scientific and business experts, and detailed knowledge of his clients’ companies to provide strategic legal counsel on a wide range of business matters. With extensive global experience, including serving as lead attorney in complex patent proceedings, trials and appeals across Asia, Europe, North America, and Australia, Chad has proven to be a results-focused, hands-on leader known for assembling and managing effective, collaborative teams across multiple time zones, firms, and languages.
Betsy Flanagan
Katie Hyma
Paul Csiszar
After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the California Bar in 1986 he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector. Currently Mr Csiszár serves as one of the Directors of the Directorate General for Competition of the European Commission.
Kelly Knaapen Arts
Kelly is Senior Director, European Patents and IP Operations at Merus. She has a Master’s degree in Biomedical Sciences and started her career as European patent attorney in private practice. In 2019 she joined Merus, where she is responsible for the operation of the IP department, directs the IP strategy, and advances Merus’ patent portfolio relating to multispecific antibodies. Working together with several outside counsel and collaboration partners, her focus is on establishing a strong IP position and freedom to operate for Merus’ key platform technology and clinical and pre-clinical products to support Merus’ mission to close in on cancer.
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.
Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
In Partnership with
Platinum Partners
Fish & Richardson
Website: https://www.fr.com/
Few firms have protected more innovative and valuable intellectual property than Fish & Richardson. We work with life sciences companies to protect and maximize the value of their IP so that they may achieve their strategic goals through partnership, licensing, financing, acquisition, and enforcement. The Fish team is comprised of accomplished patent attorneys and agents, many of whom boast Ph.D.s and extensive industry experience. Our clients choose to work with Fish attorneys because of their deep technical backgrounds, their expertise on the latest innovations in the industry, and the breadth of their experience working with life sciences companies of every size and in every field.
Pinsent Masons
Website: https://www.pinsentmasons.com/
Pinsent Masons international Life Sciences practice is one of the best in Europe.
Their team, comprising more than 100 sector specialists, many of whom are leading individuals in their field with relevant scientific degrees (some to Ph.D.) and experience, drawn from industry, is dedicated to helping their clients continue to develop cutting-edge strategies that use the law as a business enabler to positively impact their bottom line.
The team acts for businesses globally on complex market shifting transactions; cutting edge R&D collaboration; partnering and licensing deals; the most high profile, business-critical patent and regulatory litigations; and hugely impactful anti-trust investigations and litigations.
Comprising some of the world’s leading life sciences experts, the team works with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, and spot and convert opportunities.
Gold Partners
Associate Media Partner
CTC Legal Media (Patent Lawyer Magazine)
Website: https://ctclegalmedia.com/
CTC Legal Media are globally renowned publishers of The Trademark Lawyer and The Patent Lawyer Magazines, reporting on core IP matters. Each and every edition is full of exclusive special features including guest interviews with in-house counsel, case comment, and the latest developments in the IP Industry, delivered to a combined hardcopy and digital global readership of over 93,000+ IP professionals.
2023 Media Partners
JUVE
Website: https://www.juve-patent.com
JUVE has been reporting on the UPC, the European Patent Office and developments at law firms and in-house departments for twenty years – and in English since 2018.
JUVE Patent provides daily news coverage, in-depth reports and annual rankings on the four most important European patent markets.
Global Legal Group
Website: https://iclg.com/
ICLG.com is a global resource for legal reference, analysis, and news, hosting an array of comprehensive comparative legal guides and research tools that cover law in more than 150 jurisdictions across 50 practice areas.
ICLG.com also provides daily legal news and event directories. At the heart of ICLG.com is an international network of legal experts, whose knowledge and experience are highly valued by legal and business professionals around the world.
CEE Legal Matters
Website: https://ceelegalmatters.com/
CEE Legal Matters is a print and online publication for and about lawyers interested and working in Europe's emerging legal markets. CEE Legal Matters features news, interviews, analysis, opinion, and more. We also host conferences and round-tables and produce special reports on fees, salaries, and other subjects of interest to lawyers in the region. Our mission is, simply, to be the go-to source of information about lawyers and legal markets in Central and Eastern Europe.
The Global IP Matrix
Website: https://www.gipmatrix.com/
The Global IP Matrix is the only print and digital IP industry-specific publication authored by legal professionals in the intellectual property sector. Our content is 100% contributed by IP industry legal professionals for professionals in the IP field.
Industry thought leaders provide comprehensive, detailed analysis reports on innovation, IP trends, new legislation, and IP strategy, amongst other topics in the IP spectrum internationally.
We have an unbiased approach, and we welcome thought leaders at all levels to share their knowledge and experience through sharing thought-provoking content.
For more info contact us at - [email protected] or call +44 (0)203 813 045
Women's IP World
Website: https://www.womensipworld.com/
The Women's IP World Annual was launched in 2019 to highlight and celebrate the work and achievements of women working in IP, IP Law & innovation globally. Women play significant roles in IP & Innovation that should be recognised and discussed at the highest level.
We endeavour to give women from all over the world (that work in IP Law and innovation) a voice and a platform to showcase their expertise and experiences of working in the industry and receive recognition for their outstanding work and achievements with other like-minded professionals working in these fields.
Our publication has received much attention from international IP organisations like INTA and AIPPI, who have contributed the opening letters to our last two annual editions. Our yearly publication has attracted a cocktail of awe-inspiring women from all over the world who are happy to share their profiles and experience working in the industry with our global audience.
The Women's IP World annual publication is produced only once per year. It is distributed monthly for one year at IP and innovation conferences and exhibitions all over the world. Our magazine is published in a few different formats, including print, digital and now in audio format via iTunes, PodOmatic, Spotify, Audible and Amazon Music for a more unintrusive listening experience.
Women's IP World 2022 presentation - https://www.youtube.com/watch?v=6SgpYU2uWto
Gene Therapy Net
Website: www.genetherapynet.com
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network for the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
Partner With Us
Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
To discuss your objectives and partnership opportunities please contact [email protected]
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Global IP Hub Advisory Board
Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).
Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”
Fredrik Fredh
Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).
Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Lorenz Kallenbach
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.
Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.
Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Nicolas Pourbaix
Christof Bull
Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.
She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.
Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.
Alexandra Moulson
Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management, and launch.
She has over 18 years of experience in pharmaceuticals, 8 years originators, 8 years biosimilars, and 2 years generics. Alex is British, with Biochemistry and MBA degrees.
Working backward, following her MBA, Alex was at McKinsey (reaching Associate Principal), at Morphosys was the Director for Business Development and at Sandoz brought a rituximab biosimilar to market and later led the Strategy Department for Sandoz. She is currently the Chief Development Officer for Polpharma Biologics.
Mike Cottler
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Ewan Nettleton
BOOK YOUR PLACE TODAY
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Global Biologics Cell & Gene Legal Summit Testimonials
I really enjoyed the event. It was a great agenda with topics from different areas relevant to the biopharma industry. I felt that I had the opportunity to look beyond my day to day work. The speakers and discussions panels were excellent. The location was nice with good networking opportunities. A reception at the end of the event would have further improved the possibilities to network.
I really enjoyed participating in the Global Cell, Gene and Cell Therapy Legal Summit. The intimate format allowed for a good level of discussion and networking opportunities with representatives from other companies and the content of the discussion was highly relevant to my day-to-day activities.
This Global Biologics Cell and Gene Conference has been an extremely good forum for sharing views and address hop topics within the industry, I am glad I could spend the two days last week in Brussels with such a group of specialists. I am certainly looking forward to the next edition.
It was a highly specialised conference where very interesting topics of particular relevance were discussed by experts in the field. Format, location and organisation could not have been better, with multiple networking opportunities.
Our 2022 Legal Portfolio Partners Include
.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.